This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07659574 |
|---|---|
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | The United Bio-Technology (Hengqin) Co., Ltd. |
| Enrollment | 360 participants |
| Design | Interventional, Randomized, Parallel, Double-blind, Placebo-controlled |
| Conditions | Type 2 Diabetes |
| Interventions | UBT251 Injection 2.0 mg; UBT251 Injection 4.0 mg; UBT251 Injection 6.0 mg; matching placebos |
| Start | Sep 7, 2026 |
| Primary completion | Sep 24, 2027 |
| Study completion | Oct 22, 2027 |
| Results posted | Not yet |
| Registry last updated | Not stated |
Compounds on this site that cite this trial
What the registry says the trial is about
Phase 3 trial of UBT251 injection against placebo in adults with type 2 diabetes who are managed with diet and exercise alone.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change in HbA1c from baseline | Week 40 |
5 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 1, 2026. See the trial changes feed for what has changed recently.
More trials of UBT251
- UNIGUIDE-2: UBT251 Phase 3 Against Semaglutide in Type 2 Diabetes (Phase 3 NCT07653477)
- UBT251 Dose-Finding Study in Type 2 Diabetes (Novo Nordisk Phase 2) (Phase 2 NCT07668388)
- UBT251 Injection Phase II Study in Type 2 Diabetes, With Semaglutide Comparator (Phase 2 NCT07163624)
- UBT251 Injection Phase Ⅲ Study (OSA-PAP) (Phase 3 NCT07806851)
- UBT251 Injection Phase Ⅲ Study (OSA-NPAP) (Phase 3 NCT07767942)
- UBT251 Phase 3 in Overweight or Obesity (China) (Phase 3 NCT07648225)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
